Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$10.02 USD
-0.02 (-0.20%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $10.07 +0.05 (0.50%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.02 USD
-0.02 (-0.20%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $10.07 +0.05 (0.50%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Zacks News
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
by Zacks Equity Research
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
by Zacks Equity Research
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
Terns Surges 29.6% in Three Months: Will the Momentum Continue?
by Zacks Equity Research
TERN has outperformed the industry in the past three months on encouraging pipeline progress of its candidates. Positive data on obesity candidates should boost the stock further.
Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 78.7% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
by Zacks Equity Research
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 136.4% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know
by Zacks Equity Research
Does Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Take the Zacks Approach to Beat the Market: Uber, Baidu, AssetMark in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice
by Zacks Equity Research
Does Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com featured highlights include Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE
by Zacks Equity Research
Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE have been highlighted in this Screen of The Week article.
3 Stocks for Higher Returns as New Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Terns Pharmaceuticals (TERN), AllianceBernstein (AB) and ALLETE (ALE).
Zacks.com featured highlights include Terns Pharmaceuticals, Napco Security Technologies and AVEO
by Zacks Equity Research
Terns Pharmaceuticals, Napco Security Technologies and AVEO have been highlighted in this Screen of The Week article.
New Analysts Initiate Coverage: 3 Top-Ranked Stocks to Buy
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Terns Pharmaceuticals (TERN), Napco Security (NSSC) and AVEO.
All You Need to Know About Terns Pharmaceuticals, Inc. (TERN) Rating Upgrade to Buy
by Zacks Equity Research
Terns Pharmaceuticals, Inc. (TERN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.